


ABSTRACT OF THE DISCLOSURE

Please add new page 35 to the application containing the abstract of the disclosure as follows:

(35)

ABSTRACT OF THE DISCLOSURE


A serine protease inhibitor having the formula (I),



in which

J is H, R¹, R¹-O-C(O)-, R¹-C(O)-, R¹-SO₂-, R³OOC-(CHR²)_p-,
 (R^{2a}, R^{2b})N-CO-(CHR²)_p- or Het-CO-(CHR²)_p-;

W is an amino-acid of the formula -NH-CHR¹-C(O)-,
 -NR⁴-CH((CH₂)_qC(O)OR¹)-C(O)-,
 -NR⁴-CH((CH₂)_qC(O)N(R^{2a}, R^{2b}))-C(O)-,
 -NR⁴-CH((CH₂)_qC(O)Het)-C(O)-,
 D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3
 Piq, glutanyl or a (C₁-C₆) alkylester thereof;
 E is -NR²-CH₂- or the fragment



, which is unsubstituted or substituted
 with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;
 R¹ is selected from (1-12C)alkyl,
 (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-
 12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted
 or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo,
 OH, CF₃ or halogen, and from
 (6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and
 (14-20C)(bisary)alkyl, wherein the aryl groups are
 unsubstituted or substituted with (1-6C)alkyl,
 (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;
 R², R^{2a} and R^{2b} are each independently selected from
 H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl,

Attorney Docket Number O 98411 US

(3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen; R^3 is the same as R^2 or is Het-(1-6C)alkyl; R^4 is H or (1-3C)alkyl; X and Y are CH or N, with the proviso that they are not both N; Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S; m is 1 or 2; p is 1, 2 or 3; q is 1, 2 or 3; t is 2, 3 or 4; or a pharmaceutically acceptable addition salt or solvate thereof.